Wall Street expects a year-over-year increase in earnings on higher revenues when Avis Budget Group (CAR) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Octo ...

Although benchmark interest rates have been moving down, there has been some downward pressure on the share price of REITs as the uncertain economic climate puts pressure on the disposable income. Interestingly, residential REITs are alsoHe is the leader of the investment group European Small Cap Ideas which offers exclusive access to actionable research on appealing Europe-focused investment opportunities not found elsewhere. The a focus is on high-quality ideas in the small-cap space, with emphasis on cap ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against America's Car-Mart, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Car-Mart has engaged in unlawful practices that may have led to financial losses for investors [1][2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Performance and Stock Impact - On July 15, 2025, Car-Mart announced a delay in filing its annual report due to the need for enhanced disclosures regarding loan modifications, resulting in a stock price drop of $3.12 (5.2%) to $57.26 [7]. - On July 30, 2025, Car-Mart disclosed that certain financial statements should no longer be relied upon, leading to a further stock price decline of $3.70 (7.5%) to $45.57 [7]. - On September 4, 2025, Car-Mart reported a 5.7% decline in sales volumes, causing its stock price to fall by $8.14 (18.2%) to $36.51 [7].

Conference Call to Discuss Results Scheduled for October 28th, 2025PARSIPPANY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its third quarter 2025 results after the market close on Monday, October 27th, 2025, and to host a conference call for institutional investors to discuss these results on Tuesday, October 28th, 2025, at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. I ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against America's Car-Mart, Inc. regarding possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Car-Mart has engaged in unlawful business practices that may have harmed investors [1][2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Performance and Stock Impact - On July 15, 2025, Car-Mart announced a delay in filing its annual report due to the need for enhanced disclosures related to loan modifications, resulting in a stock price drop of $3.12 (5.2%) to close at $57.26 [5]. - On July 30, 2025, Car-Mart disclosed that certain previously issued financial statements were no longer reliable, leading to a further stock price decline of $3.70 (7.5%) to close at $45.57 [5]. - On September 4, 2025, Car-Mart reported a 5.7% decline in sales volumes, causing its stock price to fall by $8.14 (18.2%) to close at $36.51 [5].

CAR Group Limited - CAR Group has been a leading operator of online marketplaces for vehicles since the 1990s, focusing on simplifying the buying and selling process for users [1][2] - The company has experienced steady growth and operates globally in markets such as Australia, South Korea, the United States, and Chile [3] - CAR has achieved a revenue growth rate of 37.0% per year since 2021, reaching $1,099 million in FY24, with net profit increasing from $131 million to $250 million during the same period [6] Transurban Group - Transurban, founded in 1999, manages and develops urban toll road networks in Australia, Canada, and the United States, with interests in 22 urban motorways [4] - The company invests heavily in new projects funded through toll revenue from motor vehicles [4] - In FY24, Transurban reported a debt/equity ratio of 175.1%, indicating a leveraged position, and an ROE of 3.0%, which is below the expected threshold for a mature business [7][8] - Since 2020, Transurban has maintained an average dividend yield of 3.6% per year [8]

Shares of Avis Budget Group (NASDAQ: CAR ) have been an excellent performer over the past year, basically doubling in value. Given its highly leveraged balance sheet, CAR's fair value can move significantly with modest changes in used carOver fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let me know ...

PRINCETON, N.J. and NEW YORK , Sept. ...

Core Viewpoint - Anixa Biosciences has completed dosing of the fourth cohort in its Phase 1 clinical trial for a novel FSHR-targeted CAR-T/CER-T therapy aimed at treating recurrent ovarian cancer, maintaining a positive safety profile throughout the trial [1] Group 1 - The company is focused on the treatment and prevention of cancer [1] - The ongoing clinical trial is registered under ClinicalTrials.gov with the identifier NCT05316129 [1] - No dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity have been observed in the trial [1]

Core Insights - Kyverna Therapeutics is advancing its CAR T-cell therapy, KYV-101, which has the potential to provide durable, drug-free, disease-free remission for patients with myasthenia gravis (MG) and stiff person syndrome (SPS) [3][24] - The company has designed an innovative Phase 3 trial for MG, aligning with FDA requirements, which is expected to facilitate a clear path to Biologics License Application (BLA) [4][6] - The virtual KOL event will showcase positive long-term data from compassionate use patients and insights from key opinion leaders (KOLs) regarding the potential of CD19 CAR T-cell therapy in autoimmune diseases [2][9] Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with KYV-101 as its lead candidate [25] - The company is also conducting multi-center Phase 1/2 trials for lupus nephritis and exploring other autoimmune indications, including multiple sclerosis and rheumatoid arthritis [25] Clinical Trial Details - The KYSA-6 Phase 2/3 trial for MG is an open-label, randomized, controlled study aimed at demonstrating the superiority of KYV-101 over standard-of-care treatments [5][6] - The trial will enroll approximately 60 patients, randomized to receive either KYV-101 or continue with standard-of-care therapy, with co-primary endpoints focusing on changes in MG-ADL and QMG scores at 24 weeks [7][8] - The trial design allows for the assessment of KYV-101 as a standalone treatment, evaluating its potential for durable remission without concurrent immunosuppressive therapy [6][7] Disease Background - Myasthenia gravis is a neuromuscular autoimmune disease characterized by muscle weakness and fatigue, often leading to severe complications such as respiratory failure [22] - Stiff person syndrome is a rare autoimmune disease marked by muscle stiffness and spasms, resulting in significant mobility impairment and disability [23] Future Expectations - Kyverna expects to initiate patient enrollment in the Phase 3 portion of the KYSA-6 trial by the end of 2025 and plans to report interim data from the Phase 2 portion in the fourth quarter of 2025 [4][8]